Figure 2.
Figure 2. Event-free survival and overall survival of myeloma patients aged 50 to 70 treated with melphalan at 100 mg/m2 (MEL100) or oral melphalan and prednisone (MP).

Event-free survival and overall survival of myeloma patients aged 50 to 70 treated with melphalan at 100 mg/m2 (MEL100) or oral melphalan and prednisone (MP).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal